5.4 Scientific Rationale for Study Design............................................................... 5.4.1 Rationale for BMS-986226 First-in-Human Dose (Preliminary Safety Cohorts and Part A Monotherapy) ............................................................. 5.4.2 Rationale For Treatment Duration .......................................................... 5.4.2.1 Rationale for 24-week Duration of BMS-986226 Monotherapy ..... 5.4.2.2 Rationale for 2-year Duration of BMS-986226 in Combination with Nivolumab or Ipilimumab ..................................................................... 5.4.3 Rationale for Treatment Beyond Progression ......................................... 5.5 Justification for Dose and Schedules for BMS-986226, Nivolumab, and Ipilimumab ........................................................................................................ 5.5.1 Rationale for BMS-986226 Flat Dosing and Schedule ............................ 5.5.2 Rationale for Nivolumab Dose Selection ................................................. 5.5.3 Rationale for Ipilimumab Dose Schedule ................................................ 5.5.4 Rationale for Dose-escalation Phase Design .......................................... 6 STUDY POPULATION ............................................................................................